On November 1, the opening ceremony of Porton Biologics’ Gene and Cell Therapy CDMO Platform was held in Suzhou, China.   Committed to building an end-to-end gene and cell therapy CDMO service platform, Porton Biologics has finished phase one construction of the project. R&D labs of 1200 square meters and GMP workshops of 4000 square meters have all been put into use, providing CDMO services—plasmid, viral vector and cell therapy—from process development to clinical GMP production.   Founded...